FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab
We analyzed FcγRIIIA-158V/F and FcγRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Ferrata Storti Foundation
2007-08-01
|
| Seri Bilgileri: | Haematologica |
| Online Erişim: | https://haematologica.org/article/view/4544 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|